Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
suggests that paclitaxel is active in cisplatin-resistant cancer. 68.1% of cisplatinresistant cells were sensitive to paclitaxel. Paclitaxel as a single agent had a response rate of 22% in patients with platinum-resistant ovarian cancer (n = 1918), a significant increase from the response of oxaliplatin (p<0.01). Paclitaxel-resistant cells were also sensitive to cisplatin, suggesting that alternating between agents may be beneficial.
Studies of single agent paclitaxel in platinum-resistant ovarian cancer where patients had previously received paclitaxel had an improved response rate of 35.3% n=232 (p<0.01), suggesting that pre-treatment with paclitaxel improves the response of salvage paclitaxel therapy.
Conclusions: Cellular models reflect the resistance observed in the clinic as the cross resistant agent oxaliplatin has a lower response rate compared to the non-cross resistant agent paclitaxel in cisplatin-resistant ovarian cancer. Alternating therapy with cisplatin and paclitaxel may therefore lead to an improved response rate in ovarian cancer. Cisplatin and oxaliplatin target the DNA whereas paclitaxel, a taxane, causes toxicity by stabilising polymerised microtubules. Due to their differing mechanisms of action platinums and taxanes are often combined in cancer therapy. Our laboratory has found that when cells become resistant to platinum they often become sensitive to taxanes (3;4) . Preliminary reading of the literature also suggested that the reverse is also true i.e. that taxane-resistant cell lines can be sensitive to platinum. We undertook this systematic review to identify, describe and critique the clinical and cellular evidence for the use of oxaliplatin or paclitaxel in patients with cisplatin-resistant cancer. Figure 1A shows that the majority of models of acquired platinum resistance are cross-resistant to both cisplatin and oxaliplatin having at least 2-fold resistance to both drugs. The lower level resistant models, below 10-fold, tend to be cross-resistant to a similar level to both drugs. However, the higher level resistant models, above 10-fold, are highly resistant to their selecting drug and then exhibit a lower level of resistance to the other drug. This suggests that a common mechanism of low-level resistance to both cisplatin and oxaliplatin develops at clinical levels of drug treatment. Whereas the resistance mechanisms that develop at higher drug concentrations are likely to be more specific for the selecting drug. This is in contrast with the cross resistance relationship between cisplatin and carboplatin which shows cross resistance at low and high level resistance, indicated by grey shading (6) ( Figure 1B ).
The literature search for models of acquired resistance which report cross resistance data for both cisplatin and paclitaxel identified 137 cell lines (6) . For each cell line the fold paclitaxel resistance was plotted against the fold cisplatin resistance, allowing an analysis of the pattern of cross resistance between the two compounds (Figure 2A ).
13.9% of cell lines found in the literature review were below 2-fold resistance to both compounds and therefore classed as non-resistant indicated with black stars in Figure   2A . It is the minority of cell models of acquired resistance which are cross-resistant (open circles) to both cisplatin and paclitaxel (16.8%). The majority of cells are either non-cross resistant (grey circles 40.9%), with no gain of resistance to the other compound, or hypersensitive (black circles 28.5%) becoming more sensitive than the parental cancer cell line they were derived from. 71 cell lines were resistant to cisplatin, 48 of these were non-cross resistant or hypersensitive to paclitaxel (67.6%).
69 cell lines were resistant to paclitaxel, 46 of these were non-cross resistant or hypersensitive to cisplatin (66.6%). This suggests an inverse relationship between cisplatin and paclitaxel resistance in resistant cell models where resistance to one leads to sensitivity to the other. A similar inverse relationship was observed between cisplatin and docetaxel, carboplatin and paclitaxel and carboplatin and docetaxel, suggesting that an inverse resistance relationship exists between platinum and taxane chemotherapy (6).
The resistant cell lines found in the cisplatin/paclitaxel systematic review were diverse in type of carcinoma ( Figure 2B ). Ovarian (45.3%) and SCLC (21.2%) were the most common carcinomas used to develop cell lines, however, the other 16 types of carcinoma suggest that the inverse relationship between cisplatin and paclitaxel resistance is not cell type specific and could apply to all cancers. The chemotherapeutics used to develop the resistant models were also diverse, the most common were cisplatin (37.2%) and paclitaxel (20.4%) ( Figure 2C ). The other 31 agents are diverse mechanistically, suggesting that when cells become resistant to any agent there are two distinct paths available, one which leads to cross resistance to cisplatin and the other to paclitaxel.
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian carcinomas. Initial platinum responsiveness in ovarian cancer is high, but up to 80% of patients will eventually relapse and become platinum resistant (7) . Clinical platinum resistance is variably defined in the clinic and as such it is difficult to make comparisons of treatment activity between trials. However, many second-line ovarian carcinoma studies use Markman's criteria (8) where disease progression with a platinum free interval of less than 6 months is considered platinum resistant. Our search of the literature for single agent oxaliplatin salvage therapy in platinumresistant ovarian carcinoma identified 4 studies. The response rate (RR) of the platinum-resistant cohort was very low RR 8%, n = 91 compared to the platinumsensitive cohort RR 42%, n = 50 (p < 0.05 Chi-squared) (5). This suggests that there is no special activity of oxaliplatin in cisplatin-resistant cancer and correlates with the in vitro data suggesting that there is cross-resistance between cisplatin and oxaliplatin at clinically relevant levels of resistance. Oxaliplatin performed better in combination with other agents for the treatment of cisplatin-resistant cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance (5) . Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer.
Our search of the literature for single agent paclitaxel salvage therapy in platinumresistant ovarian carcinoma identified 56 studies. In order to analyse if the inverse relationship between cisplatin and paclitaxel resistance observed in resistant cell models is apparent in clinical trials, the studies were divided into two groups, paclitaxel naïve ovarian cancer or paclitaxel pre-treated ovarian cancer. The paclitaxel naïve cisplatin resistant patients had a higher response rate of 22%, n = 1918 compared to the 8% response rate to oxaliplatin (p < 0.01). This again correlates with the in vitro data, there is a better response to the non-cross resistant agent paclitaxel than the cross resistant agent oxaliplatin (Figure 3) . What was unexpected was platinum-resistant patients who have previously received paclitaxel therapy responded better to single agent paclitaxel (RR 35.3% n = 232) than the paclitaxel naïve patients (RR 22.7% n = 1918) (p <0.01 Chi-squared) (Figure 3 ) (6). Both cohorts of patients had very similar age, performance status, FIGO stage, and number of cycles of prior chemotherapy, there was a difference in histology but this did not account for this difference in response rates (6) . Usually if patients have received a drug and experienced disease progression, they are less likely to respond to therapy with a subsequent exposure to the same drug. Although one must be cautious in interpreting these summary findings due to the potential for biases in pooling of patients across studies, if the findings do reflect the true clinical response to these agents, they suggest that initial co-treatment with platinum and paclitaxel may improve the outcome of paclitaxel salvage therapy.
Conclusions
Oxaliplatin is not highly active in cisplatin resistant cancer, this appears to be due to cross resistance between cisplatin and oxaliplatin at clinically relevant levels of resistance. This provides some insight into the mechanisms of resistance to these agents, low level resistance provides cross resistance to both but at higher levels of resistance the mechanisms diverge. Paclitaxel has higher activity in cisplatin-resistant ovarian cancer, supporting the inverse resistance phenotype observed in cell models.
Paclitaxel salvage chemotherapy has higher activity in ovarian cancer patients who have received prior paclitaxel therapy suggesting that alternating between agents could improve response rates. Cisplatin Fold Resistance Paclitaxel Fold Resistance A P a r e n t a l C e l l L i n e C l i n i c a l R e s i s t a n c e 
